Literature DB >> 20470757

PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling.

Ludovic Martinet1, Christine Jean, Gilles Dietrich, Jean-Jacques Fournié, Rémy Poupot.   

Abstract

Natural killer (NK) and unconventional gammadelta T cells, by their ability to sense ligands induced by oncogenic stress on cell surface and to kill tumor cells without a need for clonal expansion, show a great therapeutic interest. They use numerous activating and inhibitory receptors which can function with some independence to trigger or inhibit destruction of target cells. Previous reports demonstrated that PGE(2) is able to suppress the destruction of some tumor cell lines by NK and gammadelta T cells but it remained uncertain if PGE(2) interferes with the different activating receptors governing the cytolytic responses of NK and gammadelta T cells. In this report, using the model of specific redirected lysis of the mouse FcgammaR(+) cell line P815, we clearly demonstrate that the major NK receptors (NKR): NKG2D, CD16 and natural cytotoxicity receptors (NCR: NKp30, NKp44, NKp46) and gammadelta T cell receptors TCR Vgamma9Vdelta2, NKG2D and CD16 are all inhibited by PGE(2). As is the case with gammadelta T cells, we show that PGE(2) binds on E-prostanoid 2 (EP2) and EP4 receptors on NK cells. Finally, we delineate that the signaling of the blockade by PGE(2) is mediated through a cAMP-dependent activation of PKA type I which inhibits early signaling protein of cytotoxic cells. In the discussion, we focused on how these data should impact particular approaches in the treatment of cancer. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470757     DOI: 10.1016/j.bcp.2010.05.002

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  44 in total

1.  Prostaglandin E2 Reverses the Effects of DNA Methyltransferase Inhibitor and TGFB1 on the Conversion of Naive T Cells to iTregs.

Authors:  Mehmet Sahin; Emel Sahin
Journal:  Transfus Med Hemother       Date:  2019-09-19       Impact factor: 3.747

2.  Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4.

Authors:  Dawn M Holt; Xinrong Ma; Namita Kundu; Peter D Collin; Amy M Fulton
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

Review 3.  Role of prostanoids in gastrointestinal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

Review 4.  Multifaceted roles of PGE2 in inflammation and cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Semin Immunopathol       Date:  2012-09-21       Impact factor: 9.623

Review 5.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

6.  Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

Authors:  Daniel Gonnermann; Hans-Heinrich Oberg; Christian Kellner; Matthias Peipp; Susanne Sebens; Dieter Kabelitz; Daniela Wesch
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 7.  Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Authors:  G O'Callaghan; A Houston
Journal:  Br J Pharmacol       Date:  2015-10-26       Impact factor: 8.739

Review 8.  Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer.

Authors:  Xiu Chen; Peng Lu; Lin Chen; Su-jin Yang; Hong-Yu Shen; Dan-dan Yu; Xiao-hui Zhang; Shan-liang Zhong; Jian-hua Zhao; Jin-hai Tang
Journal:  Tumour Biol       Date:  2015-09-17

Review 9.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

Review 10.  Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology.

Authors:  Hedi Harizi
Journal:  Cell Mol Immunol       Date:  2013-03-25       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.